Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with...

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Clinical oncology Vol. 19; no. 1; pp. 37 - 50
Main Authors:	Kraehenbuehl, Lukas, Weng, Chien-Huan, Eghbali, Shabnam, Wolchok, Jedd D, Merghoub, Taha
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.01.2022
Subjects:	Adenosine BTLA protein Cancer Clinical trials CTLA-4 protein Glucose metabolism Humans Immune checkpoint Immune checkpoint inhibitors Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunologic Factors - metabolism Immunomodulation Immunomodulators Immunotherapy Immunotherapy - methods Lymphocytes Lymphocytes T Metabolism Neoplasms - therapy Patients PD-1 protein PD-L1 protein Receptor mechanisms Signal transduction T cell receptors Tumor necrosis factor Tumors
ISSN:	1759-4774, 1759-4782, 1759-4782
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!